UA72539C2 - Pharmaceutical formulation for oral or topical administration (variants) and method for its manufacture - Google Patents
Pharmaceutical formulation for oral or topical administration (variants) and method for its manufacture Download PDFInfo
- Publication number
- UA72539C2 UA72539C2 UA2002032078A UA2002032078A UA72539C2 UA 72539 C2 UA72539 C2 UA 72539C2 UA 2002032078 A UA2002032078 A UA 2002032078A UA 2002032078 A UA2002032078 A UA 2002032078A UA 72539 C2 UA72539 C2 UA 72539C2
- Authority
- UA
- Ukraine
- Prior art keywords
- esters
- component
- fatty acids
- composition
- polyglyceryl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 238000011200 topical administration Methods 0.000 title abstract description 5
- 238000004519 manufacturing process Methods 0.000 title description 7
- 239000000203 mixture Substances 0.000 claims abstract description 121
- 150000002148 esters Chemical class 0.000 claims abstract description 40
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 39
- 239000000194 fatty acid Substances 0.000 claims abstract description 39
- 229930195729 fatty acid Natural products 0.000 claims abstract description 39
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 36
- 229920000223 polyglycerol Polymers 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229960003511 macrogol Drugs 0.000 claims abstract description 30
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 29
- 125000005456 glyceride group Chemical group 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 230000036961 partial effect Effects 0.000 claims abstract description 12
- 238000010790 dilution Methods 0.000 claims abstract description 11
- 239000012895 dilution Substances 0.000 claims abstract description 11
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 10
- -1 triglyceride macrogol glycerol esters Chemical class 0.000 claims abstract description 9
- 108010036949 Cyclosporine Proteins 0.000 claims description 35
- 239000000126 substance Substances 0.000 claims description 35
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 34
- 229930182912 cyclosporin Natural products 0.000 claims description 33
- 229960001265 ciclosporin Drugs 0.000 claims description 31
- 239000006185 dispersion Substances 0.000 claims description 25
- 239000004359 castor oil Substances 0.000 claims description 24
- 235000019438 castor oil Nutrition 0.000 claims description 24
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 24
- 229930105110 Cyclosporin A Natural products 0.000 claims description 19
- 239000007903 gelatin capsule Substances 0.000 claims description 13
- 229920006395 saturated elastomer Polymers 0.000 claims description 13
- 108010036941 Cyclosporins Proteins 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 12
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 229930012538 Paclitaxel Natural products 0.000 claims description 8
- 229940123237 Taxane Drugs 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229940049918 linoleate Drugs 0.000 claims description 8
- 229960001592 paclitaxel Drugs 0.000 claims description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 8
- 239000003349 gelling agent Substances 0.000 claims description 7
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 6
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims description 6
- 239000007863 gel particle Substances 0.000 claims description 6
- 229940070765 laurate Drugs 0.000 claims description 6
- 229940105132 myristate Drugs 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- 101800001776 Nuclear inclusion protein B Proteins 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 6
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 6
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 6
- 239000005642 Oleic acid Substances 0.000 claims 6
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 6
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 6
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 4
- JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 claims 2
- JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 claims 2
- UUKQNWJVWJLTEU-UHFFFAOYSA-N Cyclosporin Y Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O UUKQNWJVWJLTEU-UHFFFAOYSA-N 0.000 claims 2
- 108010019248 cyclosporin C Proteins 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims 2
- 150000002194 fatty esters Chemical class 0.000 claims 1
- 150000002314 glycerols Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 13
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract description 4
- 238000009472 formulation Methods 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- 239000002245 particle Substances 0.000 description 33
- 231100000693 bioaccumulation Toxicity 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 16
- 239000000499 gel Substances 0.000 description 15
- 239000004615 ingredient Substances 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 10
- 239000004530 micro-emulsion Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 229940055577 oleyl alcohol Drugs 0.000 description 7
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 6
- 150000002191 fatty alcohols Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229940049964 oleate Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 238000007127 saponification reaction Methods 0.000 description 4
- 229940114926 stearate Drugs 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 235000019489 Almond oil Nutrition 0.000 description 3
- 239000008168 almond oil Substances 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 3
- 229960001597 nifedipine Drugs 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229940100688 oral solution Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000012798 spherical particle Substances 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 230000002535 lyotropic effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000011044 succinic acid Nutrition 0.000 description 2
- 150000003444 succinic acids Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 229940114069 12-hydroxystearate Drugs 0.000 description 1
- WOKDXPHSIQRTJF-UHFFFAOYSA-N 3-[3-[3-[3-[3-[3-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)CO WOKDXPHSIQRTJF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010001513 AIDS related complex Diseases 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 101100310222 Caenorhabditis briggsae she-1 gene Proteins 0.000 description 1
- 101100494265 Caenorhabditis elegans best-15 gene Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241001397104 Dima Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000642333 Homo sapiens Survival of motor neuron-related-splicing factor 30 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 101100229738 Mus musculus Gpank1 gene Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 239000003568 Sodium, potassium and calcium salts of fatty acids Substances 0.000 description 1
- 102100036412 Survival of motor neuron-related-splicing factor 30 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 238000004859 neutralization-reionization mass spectrometry Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- DOKHEARVIDLSFF-UHFFFAOYSA-N prop-1-en-1-ol Chemical class CC=CO DOKHEARVIDLSFF-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 235000013875 sodium salts of fatty acid Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9919288A GB2355656B (en) | 1999-08-17 | 1999-08-17 | Pharmaceutical compositions for oral and topical administration |
| PCT/GB2000/003161 WO2001012229A1 (en) | 1999-08-17 | 2000-08-17 | Pharmaceutical compositions for oral and topical administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA72539C2 true UA72539C2 (en) | 2005-03-15 |
Family
ID=10859192
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002032078A UA72539C2 (en) | 1999-08-17 | 2000-08-17 | Pharmaceutical formulation for oral or topical administration (variants) and method for its manufacture |
| UA20031212327A UA75926C2 (en) | 1999-08-17 | 2003-12-24 | Pharmaceutical composition for oral or local use and method for manufacture thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20031212327A UA75926C2 (en) | 1999-08-17 | 2003-12-24 | Pharmaceutical composition for oral or local use and method for manufacture thereof |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US20070190132A1 (ru) |
| EP (2) | EP1210119B1 (ru) |
| JP (2) | JP2003507343A (ru) |
| KR (2) | KR100828747B1 (ru) |
| CN (2) | CN101406453A (ru) |
| AR (2) | AR025324A1 (ru) |
| AT (2) | ATE402691T1 (ru) |
| AU (1) | AU777740B2 (ru) |
| BR (1) | BR0013385A (ru) |
| CA (2) | CA2452118A1 (ru) |
| CO (1) | CO5380014A1 (ru) |
| CY (1) | CY1105318T1 (ru) |
| CZ (2) | CZ296170B6 (ru) |
| DE (2) | DE60018081T2 (ru) |
| DK (2) | DK1334717T3 (ru) |
| EE (2) | EE04955B1 (ru) |
| EG (1) | EG23994A (ru) |
| ES (2) | ES2311077T3 (ru) |
| GB (1) | GB2355656B (ru) |
| HK (1) | HK1049629A1 (ru) |
| HR (1) | HRP20020154B1 (ru) |
| HU (1) | HUP0203236A3 (ru) |
| IL (4) | IL158108A0 (ru) |
| JO (1) | JO2324B1 (ru) |
| MX (1) | MXPA02001631A (ru) |
| NO (2) | NO20020760L (ru) |
| NZ (1) | NZ517271A (ru) |
| PE (1) | PE20010636A1 (ru) |
| PL (1) | PL192769B1 (ru) |
| PT (2) | PT1210119E (ru) |
| RU (2) | RU2279894C2 (ru) |
| SA (1) | SA00210487B1 (ru) |
| SG (1) | SG143019A1 (ru) |
| SI (1) | SI1210119T1 (ru) |
| SK (2) | SK286083B6 (ru) |
| TN (1) | TNSN00173A1 (ru) |
| UA (2) | UA72539C2 (ru) |
| UY (1) | UY26303A1 (ru) |
| WO (1) | WO2001012229A1 (ru) |
| ZA (2) | ZA200308221B (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2355656B (en) * | 1999-08-17 | 2004-04-07 | Galena As | Pharmaceutical compositions for oral and topical administration |
| FR2826261B1 (fr) * | 2001-06-26 | 2005-03-25 | Lmd | Composition a usage topique comprenant un produit cytotoxique et son utilisation dans le traitement de l'alopeche |
| DE10154464B4 (de) * | 2001-11-08 | 2005-10-20 | Max Delbrueck Centrum | Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol |
| KR20030065831A (ko) * | 2002-02-01 | 2003-08-09 | 주식회사 태평양 | 사이클로스포린을 함유한 지속 방출형 약학적 조성물 |
| US7101576B2 (en) | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
| US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
| EP1935407A1 (en) * | 2002-12-03 | 2008-06-25 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
| JP4518042B2 (ja) * | 2002-12-04 | 2010-08-04 | 日油株式会社 | コエンザイムｑ１０を含有する水溶性組成物の製造方法 |
| EP1582206A4 (en) * | 2002-12-04 | 2010-09-22 | Nisshin Pharma Inc | WATER-SOLUBLE COMPOSITION WITH COENZYM Q10 |
| KR20200083657A (ko) * | 2002-12-09 | 2020-07-08 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| US6979672B2 (en) * | 2002-12-20 | 2005-12-27 | Polichem, S.A. | Cyclosporin-based pharmaceutical compositions |
| TW200616681A (en) * | 2004-10-05 | 2006-06-01 | Recordati Ireland Ltd | Lercanidipine capsules |
| US8236286B2 (en) * | 2004-10-20 | 2012-08-07 | Kao Corporation | Liquid compositions for the oral cavity |
| BRPI0608173A2 (pt) * | 2005-02-24 | 2010-11-09 | Elan Pharma Int Ltd | composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo |
| AU2009319167A1 (en) * | 2008-11-28 | 2010-06-03 | Lectio Pharmaentwicklungs-Und Verwertungs Gmbh | Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester |
| SI2405892T1 (sl) * | 2009-03-12 | 2013-06-28 | Lectio Pharmaentwicklungs- Und Verwertungs Gmbh | Farmacevtska formulacija, ki obsega ketoprofen in polioksialkilenski ester hidroksimaščobne kisline |
| KR101100933B1 (ko) * | 2009-04-23 | 2012-01-02 | 한국기술교육대학교 산학협력단 | 솔더 볼 제거 장치 |
| WO2016160412A1 (en) * | 2015-03-27 | 2016-10-06 | Arch Personal Care Products, Lp | Viscosity building composition for personal care products |
| CN112426403B (zh) * | 2020-12-09 | 2021-09-17 | 南京天纵易康生物科技股份有限公司 | 一种口腔溃疡凝胶及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6007840A (en) * | 1988-09-16 | 1999-12-28 | Novartis Ag | Pharmaceutical compositions comprising cyclosporins |
| KR0148748B1 (ko) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| CZ288631B6 (cs) * | 1996-01-18 | 2001-08-15 | Galena, A. S. | Léčivé přípravky s obsahem cyklosporinu |
| CZ288739B6 (cs) * | 1996-08-01 | 2001-08-15 | Galena, A. S. | Cyklosporin obsahující léčivé přípravky |
| CZ267796A3 (cs) * | 1996-09-12 | 1998-04-15 | Galena A.S. | Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů |
| WO1998040094A1 (en) * | 1997-03-12 | 1998-09-17 | Abbott Laboratories | Hydrophilic binary systems for the administration of cyclosporine |
| JP2001515491A (ja) * | 1997-03-12 | 2001-09-18 | アボツト・ラボラトリーズ | 親油性化合物の投与のための親油性二成分系 |
| BR9811058A (pt) * | 1997-07-29 | 2000-09-05 | Upjohn Co | Formulação auto-emulsificante para compostos lipofìlicos |
| US6063762A (en) * | 1997-12-05 | 2000-05-16 | Chong Kun Dang Corp. | Cyclosporin-containing microemulsion preconcentrate composition |
| US20030216303A1 (en) * | 1998-03-06 | 2003-11-20 | Michael Ambuhl | Emulsion preconcentrates containing cyclosporin or a macrolide |
| GB2355656B (en) * | 1999-08-17 | 2004-04-07 | Galena As | Pharmaceutical compositions for oral and topical administration |
-
1999
- 1999-08-17 GB GB9919288A patent/GB2355656B/en not_active Revoked
-
2000
- 2000-08-17 JO JO2000302A patent/JO2324B1/en active
- 2000-08-17 CZ CZ20020575A patent/CZ296170B6/cs not_active IP Right Cessation
- 2000-08-17 CA CA002452118A patent/CA2452118A1/en not_active Abandoned
- 2000-08-17 CO CO00061955A patent/CO5380014A1/es not_active Application Discontinuation
- 2000-08-17 CZ CZ20032302A patent/CZ296591B6/cs not_active IP Right Cessation
- 2000-08-17 AT AT03008447T patent/ATE402691T1/de active
- 2000-08-17 ZA ZA200308221A patent/ZA200308221B/xx unknown
- 2000-08-17 RU RU2002106825/15A patent/RU2279894C2/ru not_active IP Right Cessation
- 2000-08-17 BR BR0013385-0A patent/BR0013385A/pt not_active Application Discontinuation
- 2000-08-17 SK SK1023-2003A patent/SK286083B6/sk not_active IP Right Cessation
- 2000-08-17 IL IL15810800A patent/IL158108A0/xx unknown
- 2000-08-17 KR KR1020027002109A patent/KR100828747B1/ko not_active IP Right Cessation
- 2000-08-17 CN CNA2008101094369A patent/CN101406453A/zh active Pending
- 2000-08-17 ES ES03008447T patent/ES2311077T3/es not_active Expired - Lifetime
- 2000-08-17 EP EP00951765A patent/EP1210119B1/en not_active Expired - Lifetime
- 2000-08-17 AT AT00951765T patent/ATE288766T1/de active
- 2000-08-17 CA CA2380951A patent/CA2380951C/en not_active Expired - Fee Related
- 2000-08-17 IL IL14820000A patent/IL148200A0/xx active IP Right Grant
- 2000-08-17 SI SI200030614T patent/SI1210119T1/xx unknown
- 2000-08-17 DK DK03008447T patent/DK1334717T3/da active
- 2000-08-17 PL PL353445A patent/PL192769B1/pl unknown
- 2000-08-17 SK SK248-2002A patent/SK2482002A3/sk unknown
- 2000-08-17 MX MXPA02001631A patent/MXPA02001631A/es active IP Right Grant
- 2000-08-17 PT PT00951765T patent/PT1210119E/pt unknown
- 2000-08-17 SG SG200305899-7A patent/SG143019A1/en unknown
- 2000-08-17 HU HU0203236A patent/HUP0203236A3/hu unknown
- 2000-08-17 WO PCT/GB2000/003161 patent/WO2001012229A1/en active IP Right Grant
- 2000-08-17 UA UA2002032078A patent/UA72539C2/uk unknown
- 2000-08-17 JP JP2001516572A patent/JP2003507343A/ja active Pending
- 2000-08-17 ES ES00951765T patent/ES2237443T3/es not_active Expired - Lifetime
- 2000-08-17 EE EEP200300371A patent/EE04955B1/xx not_active IP Right Cessation
- 2000-08-17 TN TNTNSN00173A patent/TNSN00173A1/en unknown
- 2000-08-17 UY UY26303A patent/UY26303A1/es not_active Application Discontinuation
- 2000-08-17 EE EEP200200075A patent/EE04954B1/xx not_active IP Right Cessation
- 2000-08-17 EP EP03008447A patent/EP1334717B1/en not_active Expired - Lifetime
- 2000-08-17 AU AU64613/00A patent/AU777740B2/en not_active Ceased
- 2000-08-17 CN CN00813185A patent/CN1382061A/zh active Pending
- 2000-08-17 KR KR1020057015114A patent/KR100828748B1/ko not_active IP Right Cessation
- 2000-08-17 PE PE2000000842A patent/PE20010636A1/es not_active Application Discontinuation
- 2000-08-17 DK DK00951765T patent/DK1210119T3/da active
- 2000-08-17 DE DE60018081T patent/DE60018081T2/de not_active Expired - Lifetime
- 2000-08-17 NZ NZ517271A patent/NZ517271A/en unknown
- 2000-08-18 AR ARP000104281A patent/AR025324A1/es unknown
- 2000-08-19 EG EG20001069A patent/EG23994A/xx active
- 2000-11-01 SA SA00210487A patent/SA00210487B1/ar unknown
-
2002
- 2002-02-15 NO NO20020760A patent/NO20020760L/no not_active Application Discontinuation
- 2002-02-15 ZA ZA200201315A patent/ZA200201315B/en unknown
- 2002-02-17 IL IL158108A patent/IL158108A/en not_active IP Right Cessation
- 2002-02-17 IL IL148200A patent/IL148200A/en not_active IP Right Cessation
- 2002-02-19 HR HR20020154A patent/HRP20020154B1/xx not_active IP Right Cessation
-
2003
- 2003-03-13 HK HK03101840.7A patent/HK1049629A1/zh unknown
- 2003-04-26 PT PT03008447T patent/PT1334717E/pt unknown
- 2003-08-17 DE DE60322454T patent/DE60322454D1/de not_active Expired - Lifetime
- 2003-09-10 AR ARP030103268A patent/AR043106A2/es unknown
- 2003-10-24 NO NO20034778A patent/NO20034778D0/no not_active Application Discontinuation
- 2003-11-17 RU RU2003133451/15A patent/RU2279895C2/ru not_active IP Right Cessation
- 2003-12-24 UA UA20031212327A patent/UA75926C2/uk unknown
-
2004
- 2004-03-31 JP JP2004106963A patent/JP2004238399A/ja active Pending
-
2005
- 2005-05-05 CY CY20051100574T patent/CY1105318T1/el unknown
-
2007
- 2007-04-13 US US11/786,846 patent/US20070190132A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070190132A1 (en) | Pharmaceutical compositions for oral and topical administration | |
| ES2227700T3 (es) | Preparados de capsulas blandas que contienen ciclosporina. | |
| CN105125489B (zh) | 包含阿拉泊韦的药物组合物 | |
| US20080064760A1 (en) | Spontaneously Dispersible Pharmaceutical Composition | |
| AU2003254754B2 (en) | Pharmaceutical compositions for oral and topical administration | |
| AU2006201547A1 (en) | Pharmaceutical compostions for oral and topical administration | |
| BRPI0720489A2 (pt) | Cápsulas de gelatina compreendendo um ácido | |
| CZ426798A3 (cs) | Léčivé přípravky pro perorální a topickou aplikace |